Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma

Therapeutic options for patients with multiple myeloma have multiplied in the past decade. However, multiple myeloma remains an incurable disease, and relapsed/refractory myeloma is characterized by genetic and cytogenetic alterations that drive resistance and result in progressively shorter duratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Cesar, Catamero, Donna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184840/
https://www.ncbi.nlm.nih.gov/pubmed/37197721
http://dx.doi.org/10.6004/jadpro.2023.14.3.14
Descripción
Sumario:Therapeutic options for patients with multiple myeloma have multiplied in the past decade. However, multiple myeloma remains an incurable disease, and relapsed/refractory myeloma is characterized by genetic and cytogenetic alterations that drive resistance and result in progressively shorter durations of remission to each subsequent therapy. At JADPRO Live 2022, presenters discussed the multifactorial process for choosing the right therapy for a particular patient and strategies to manage unique treatment complications associated with novel treatment modalities used for patients with relapsed/refractory multiple myeloma.

Ejemplares similares